Treatment of Acute Ocular Toxoplasmosis in Pregnancy — Second Trimester (>14 Weeks)

Acute ocular toxoplasmosis during pregnancy requires a treatment strategy that is specifically calibrated to gestational stage. The second trimester — beyond 14 weeks — defines a distinct therapeutic window with its own recommended approach, separate from first- and third-trimester management.

Clinical scenario: Pregnancy, second trimester of gestation (>14 weeks). The patient's pregnant status at this stage directly determines which agents are appropriate and how they are sequenced.

Treatment approach

Management in this trimester involves a combination antiparasitic regimen that includes folinic acid supplementation, with alternative combination options discussed for specific clinical circumstances. The complete regimen — including agent selection, dosing structure, cycle length, and decision algorithm — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

During pregnancy, the therapeutic regimens are: (1) First trimester: spiramycin, and sulfadiazine; (2) Second trimester (>14 weeks): spiramycin, sulfadiazine, pyrimethamine, and folinic acid; (3) Third trimester: spiramycin, pyrimethamine and folinic acid.
Medications are given in lower doses for three weeks and can be repeated, if required, after 21 days.
Clindamycin and azithromycin or clindamycin and atovaquone (± systemic corticosteroid) are discussed as alternatives.

DOI: 10.1007/s10792-021-01994-9

View source ↗